Late toxicity following curative treatment of testicular cancer

Seminars in Surgical Oncology

Volumn 17, Issue 4, 1999, Pages 275-281

  Kollmannsberger, Christian ^a   Kuzcyk, Markus ^b   Mayer, F ^a   Hartmann, Jörg T ^a   Kanz, Lothar ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute kidney failure chemically induced; Acute monocytic leukemia; Acute myeloid leukemia chemically induced; Acute nonlymphocytic leukemia chemically induced; Amifostine; Aminoglycoside antibiotics; Bleomycin; Carboplatin; Chromosome aberrations; Cisplatin; Cyclophosphamide; DNA topoisomerase (ATP hydrolyzing); Drug administration schedule; Drug dose response relationship; Etoposide; Germ cell and embryonic neoplasms; Germinoma; Glomerular filtration rate; Hearing disorders chemically induced; Ifosfamide; Kidney drug effects; Myelodysplastic syndromes chemically induced; Radiation induced neoplasms; Risk factors; Second primary neoplasms; Spermatogenesis; Testicular neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; TESTIS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMINOMA; HEARING LOSS, HIGH-FREQUENCY; HUMANS; KIDNEY; LEUKEMIA; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; PROGNOSIS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TESTIS; TIME FACTORS;

EID: 0032763763     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199912)17:4<275::AID-SSU9>3.0.CO;2-U     Document Type: Review

References (60)

1. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977;39:1362-1371.
2. Roth BJ, Einhorn LH, Greist A: Long-term complications of cisplatin-based chemotherapy for testis cancer [Review]. Semin Oncol 1988;15:345-350.
3. Fjeldborg P, Sorensen JB, Helkjaer PE: The long-term effect of cisplatin on renal function. Cancer 1986;58:2214-2217.
4. Daugaard G, Rossing N, Rorth M: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988;21: 163-167.
5. Hamilton CR, Bliss JM, Horwich A: The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 1989;25:185-189.
6. Groth S, Nielsen H, Sorensen JB, et al: Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 1986;17:191-196.
7. Bissett D, Kunkeler L, Zwanenburg L, et al: Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 1990;62: 655-659.
8. Osanto S, Bukman A, Van Hoek F, Sterk PJ, et al: Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992;10:574-579.
9. Moul JW, Robertson JE, George SL, et al: Complications of therapy for testicular cancer. J Urol 1989;142:1491-1496.
10. Reece PA, Stafford I, Russell J, et al: Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987;5:304-309.
11. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C: Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. In press.
12. Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994;12:1223-1231.
13. Elias AD, Ayash LJ, Eder JP, et al: A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991;9:320-327.
14. Bokemeyer C, Hartmann JT, Fels LM, Knop S et al: Amifostine protects against early cisplatin-induced renal damage and enhances CD34+ cell numbers for PBSC collection [Abstract]. Proc Am Soc Clin Oncol 1997;16:47a.
15. Thompson SW, Davis LE, Kornfeld M, et al: Cisplatin neuropathy. Clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 1984;54:1269-1275.
16. Hansen SW, Hehveg-Larsen S, Trojaborg W: Long-term neurotoxicity in patients treated with cisplatin, vinblastin, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989;7:1457-1461.
17. Higa GM, Wise TC, Crowell EB: Severe, disabling neurologic toxicity following cisplatin retreatment. Ann Pharmacother 1995; 29:134-137.
18. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-2112.
19. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77:1355-1362.
20. Marco-Algarra J, Basterra J, Marco J: Cis-diaminedichloro platinum ototoxicity. An experimental study. Acta Otolaryngol 1985;99:343-347.
21. Reddel RR, Kefford RF, Grant JM, et al: Ototoxicity in patients receiving cisplatin: importance of dose and method of administration. Cancer Treat Rep 1982;66:19-23.
22. Petersen PM, Skakkebaek NE, Vistisen K, et al: Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999;17:941-947.
23. Stephenson WT, Poirier SM, Rubin L, Einhorn LH: Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 1995;13:2278-2280.
24. Petersen PM, Hansen SW, Giwercman A, Rorth M et al: Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994;5:355-358.
25. Pont J, Albrecht W: Fertility after chemotherapy for testicular germ cell cancer [Review]. Fertil Steril 1997;68:1-5.
26. Bokemeyer C, Schmoll HJ: Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993;11:1703-1709.
27. van der Maase H, Specht L, Jacobson GK,et al: Surveillance following orchiectomy for stage I seminoma of the testis. Eur J Cancer 1993;29:1931-1934.
28. Moller H, Mellemgaard A, Jacobsen GK, et al: Incidence of second primary cancer following testicular cancer. Eur J Cancer 1993; 29A:672-676.
29. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al: Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-424.
30. Travis LB, Curtis RE, Storm H, Hall P et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-1439.
31. Bokemeyer C, Schmoll HJ: Treatment of testicular cancer and the development of secondary malignancies [Review]. Clin Oncol 1995;13:283-292
32. Travis LB, Andersson M, Holowaty E, et al: Risk of leukemia following radiotherapy and chemotherapy for testicular cancer [Abstract]. Proc Am Soc Clin Oncol 1999;18:308a.
33. Bokemeyer C, Freund M, Schmoll HJ, Rieder H et al: Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour [letter]. Ann Oncol 1992;3:772.
34. Ratain MJ, Rowley JD: Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes [Review]. Ann Oncol 1992;3:107-111.
35. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C: Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies [Review]. J Cancer Res Clin Oncol 1998;124:207-214.
36. Whitlock JA, Greer JP, Lukens JN: Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia [Review]. Cancer 1991;68:600-604.
37. Pedersen-Bjergaard J, Philip P, Larsen SO, et al: Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990;76:1083-1091.
38. Andersen MK, Johansson B, Larsen SO, Pedersen-Bjergaard J: Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 1998;83:483-488.
39. Hentrich M, Brack N, Hartenstein R: Secondary acute promyelocytic leukemia follwing etoposide containing chemotherapy for germ cell tumors (GCT) [Abstract]. Proc Am Soc Clin Oncol 1998;17:333a.
40. Roth BJ, Greist A, Kubilis PS, et al: Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 1988;6:1239-1247.
41. Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al: Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumours. Lancet 1991;338(8763):359-363.
42. Nichols CR, Breeden ES, Loehrer PJ, et al: Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993;85:36-40.
43. Bajorin DF, Motzer RJ, Rodriguez E, et al: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993;85:60-62.
44. Boshoff C, Begent RH, Oliver RT, et al: Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995;6:35-40.
45. Bokemeyer C, Schmoll HJ, Kuczyk MA, et al: Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer [letter]. J Natl Cancer Inst 1995;87:58-60.
46. Kollmannsberger C, Beyer J, Droz JP, et al: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998;16:3386-3391.
47. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-1440.
48. Smith MA, Rubinstein L, Anderson JR, Arthur D et al: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577.
49. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A et al: First-line high-dose chemotherapy compared to standard-dose PEB/ VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched pair analysis [Abstract]. Proc Am Soc Clin Oncol 1999;18:309a.
50. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351-357.
51. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C: Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer. In press.
52. Ben-Yehuda D, Krichevsky S, Caspi O, et al: Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996;88:4296-4303.
53. Karp JE, Smith MA: The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention [Review]. Semin Oncol 1997;24:103-113.
54. Felix CA, Walker AH, Lange BJ, et al: Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-13181.
55. Kaldor JM, Day NE, Band P, et al: Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987;39:571-585.
56. Coleman MP, Bell CM, Fraser P: Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study. Br J Cancer 1987;56:349-355.
57. Kleinerman RA, Liebermann JV, Li FP: Second cancer following cancer of the male genital system in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:139-147.
58. Fossa SD, Langmark F, Aass N, et al: Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 1990;61:639-643.
59. Hay JH, Duncan W, Kerr GR: Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol 1984;57(679):597-602.
60. Hanks GE, Peters T, Owen J: Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992;24:913-919.